Toreforant
id:
toreforant-188-18140498
title:
Toreforant
text:
Toreforant (JNJ-38518168) is an orally-dosed selective antagonist of the histamine H4 receptor that has been studied for various health conditions. It is the successor of a number of H4-selective compounds developed by Johnson & Johnson. Phase IIa clinical trials completed as recently as November 2018 continue to suggest that toreforant is safe. As of the end of 2020, there is no regulator-approved H4 antagonist. In U.S. Phase II clinical trials, toreforant, by itself, did not show efficacy agai
brand slug:
wiki
category slug:
encyclopedia
description:
Antagonist of the histamine H4 receptor.
original url:
https://en.wikipedia.org/wiki/Toreforant
date created:
2021-03-01T21:47:22Z
date modified:
2024-09-09T08:57:37Z
main entity:
{"identifier":"Q27290755","url":"https://www.wikidata.org/entity/Q27290755"}
image:
{"content_url":"https://upload.wikimedia.org/wikipedia/commons/7/74/Toreforant.svg","width":512,"height":179}
fields total:
13
integrity:
16